Patented capping agent
In the process of capping for nucleic acid synthesis, it has been reported that the presence of 1,3,5-trimethylhexahydro-1,3,5-triazine in the capping agent leads to the formation of undesirable adducts. Honeywell's patent describes an invention of a nucleic acid synthesis method using a capping agent that essentially does not contain 1,3,5-trimethylhexahydro-1,3,5-triazine, proposing ultra-high purity capping agents.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
Nucleic acid pharmaceutical synthesis applications, PCR primer synthesis applications, DNA array manufacturing applications.
catalog（1）
Download All Catalogs
News about this product（2）
Company information
Since its establishment in 1904 (Meiji 37) with the aim of manufacturing and selling chemical products, our company has been actively engaged in production and sales activities to contribute to various industries through research and development and production. We provide not only reagents for testing and research but also custom reagent preparation for specific applications, liquid preparation services, and contract services for organic synthesis. In recent years, we have specialized in small-scale production of research reagents related to pharmaceuticals, metabolites, functional materials, and environmental substances, and we propose contract synthesis of hard-to-obtain minor compounds to various institutions. In 2016, we signed a general agency agreement with Honeywell (Honeywell Japan Ltd.) for sales in Japan, particularly expanding our lineup of Karl Fischer moisture measurement reagents, high-purity solvents, analytical standards, and inorganic reagents. In 2019, we launched "Reagent Direct," allowing customers to place product orders and request quotes through our website, as well as check inventory and regulatory compliance, search and download SDS/product specifications/test reports, and access various services and content such as technical articles and evaluation cases. We will continue to respond quickly and accurately to our customers' diverse requests and strive to be a company that contributes to society.
![[Research Material] The Global Market for Prescription Drugs](https://image.mono.ipros.com/public/product/image/880/2001472266/IPROS88869514241408629549.jpeg?w=280&h=280)
